Pfizer’s full-year outlook has fallen short of Wall Street’s bullish expectations, sparking a sell-off in shares of the drugmaker that has been at the forefront of developing Covid-19 vaccines and treatment.
辉瑞(Pfizer)的全年展望没有达到华尔街的乐观预期，使这家一直置身于新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗和药物开发前沿的制药商的股票遭到抛售。
您已阅读8%（293字），剩余92%（3572字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。